Managing coexisting depression and substance use disorder: insights from clinical experience

Comorbid major depressive disorder (MDD) and substance use disorder (SUD) occur frequently and are challenging to manage. The negative impact of these co-occurring conditions on patient quality of life, functional ability, and mortality necessitates timely diagnosis and a multifaceted treatment approach. However, there are few evidence-based clinical guidelines for these co-occurring conditions, further adding to the complexity of treatment. Here, we provide our perspective on the management of MDD in the context of SUD using clinical evidence and our experience. Due to the chronic, relapsing nature of these disorders, long-term follow-up is required to continually assess treatment efficacy and make adjustments where needed. Antidepressants frequently used for MDD, such as selective serotonin reuptake inhibitors (SSRIs), may show variable effectiveness in patients with comorbid SUD, and antidepressant selection should be individualized according to the patient profile, disease characteristics, and type of substance being misused. Treatment options with different pharmacodynamic profiles include agomelatine, bupropion, and vortioxetine. Serotonin antagonist and reuptake inhibitors (SARIs), such as trazodone, may offer advantages in select patients, given their safety profile and potential to address depressive features commonly seen with SUD. Importantly, collaboration between a range of healthcare professionals to provide psychoeducation and pharmacological management, alongside social support that includes family, friends, and/or caregivers is needed for treatment success. Further studies specifically assessing treatments for comorbid MDD and SUD are required. In addition, training is needed to increase medical expertise and lessen stigma, which can contribute to sub-standard care.